A Model for Targeted Magnetic Lipid Nanoparticles in Brain Cancer Treatment

The BBB is a selective endothelial interface formed by tight junctions, pericytes and astrocytic end-feet that restrict the entry of most systemic drugs into the central nervous system [11,12]. Although the BBB may be locally disrupted in GBM, the resulting BTB remains heterogeneously permeable. This regional variability causes uneven drug distribution, with poorly perfused tumour regions remaining inaccessible to most small molecules and biologics.

Furthermore, endothelial cells in the BBB and BTB express high levels of efflux pumps such as P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), which actively transport chemotherapeutic agents back into the circulation [13]. This severely limits the brain uptake of many systematically administered drugs and contributes to subtherapeutic concentrations in the tumour core.

The GBM microenvironment presents additional biophysical and biochemical barriers. The extracellular matrix is highly dense and irregular, impeding nanoparticle penetration [14]. Hypoxia and necrosis are common, creating an acidic and immunosuppressive milieu that supports angiogenesis, tumour invasion, and resistance to radiotherapy and chemotherapy.

Tumour-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Treg) further contribute to immune evasion and therapeutic resistance. These immune cells can also internalise drug carriers nonspecifically, reducing delivery efficiency to glioma cells.

GBM is characterised by rapid mutation rates and high intratumoural heterogeneity. As a result, subclonal populations with therapy-resistant phenotypes frequently emerge. Upregulation of DNA repair enzymes such as MGMT confers resistance to alkylating agents such as temozolomide [12,15]. Parallel activation of redundant signalling pathways (e.g., EGFR, PI3K/AKT/mTOR) enables escape from targeted therapies [12,13].

Additionally, the adaptive expression of efflux transporters and anti-apoptotic proteins under therapeutic pressure further reduces the effectiveness of chemotherapeutics [13,16]. The dynamic and adaptable nature of GBM requires delivery systems that can not only reach the tumour but also remain effective in the face of evolving resistance mechanisms.

The foundational structure of MF-R-LNs is a lipid-based carrier, selected for its biocompatibility, ability to encapsulate both hydrophobic and hydrophilic drugs, and ease of surface modification [7,17]. The lipid bilayer can be formulated to include phase-transition lipids or thermosensitive elements that respond to external triggers such as heat or magnetic fields [18]. A representative design of a ligand-functionalised MF-R-LN is shown in Figure 2.

In the nanoparticle core, superparamagnetic iron oxide nanoparticles (SPIONs) are embedded to enable magnetic steering and hyperthermia. SPIONs are well characterised and have been used clinically in diagnostic and therapeutic contexts [9]. Their inclusion allows for both passive and active guidance across the BBB and for localised activation using an alternating magnetic field [19].

Polyethylene glycol (PEG) is commonly grafted onto the nanoparticle surface to reduce opsonization by the mononuclear phagocyte system and extend systemic circulation time. While PEGylation improves stealth properties, it may reduce cell uptake, necessitating the inclusion of targeting ligands to compensate [20,21,22].

Surface functionalisation with targeting ligands enhances selectivity toward tumour-specific receptors overexpressed in GBM. Candidate ligands include peptides (e.g., angiopep-2, RGD) [23,24,25], antibodies (e.g., anti-EGFR), aptamers, or small molecules such as folate. These ligands can be conjugated via stable or cleavable linkers depending on the desired release profile and microenvironmental triggers.

Receptor targets must be chosen based on expression patterns in GBM cells versus healthy brain tissue. Ideal targets include the following:EGFR and EGFRvIII: commonly overexpressed in IDH-wildtype tumours and associated with poorer prognosisIL-13Rα2: high specificity to GBM cellsIntegrins (e.g., αvβ3, αvβ5): involved in tumour angiogenesis and invasionTransferrin receptor (TfR): facilitates BBB crossing [26]

Given marked inter- and intra-patient heterogeneity, ligand choice should be patient-informed wherever feasible, via biopsy immunophenotyping (e.g., receptor panels for LRP1, TfR, EGFR/EGFRvIII, IL-13Rα2) or liquid-biopsy surrogates (circulating tumour DNA/exosomes), together with imaging biomarkers. In practice, a dual-ligand design that pairs a BBB-transcytosis shuttle (e.g., Angiopep-2 or a TfR-directed binder) with ≥1 tumour-binding ligand selected from the patient's profile helps preserve target engagement despite spatial heterogeneity and temporal evolution.

Table 1 summarises representative ligand–receptor pairs relevant to GBM. Ligand selection should balance affinity and specificity: very high-affinity binders risk off-target binding and sink effects, whereas low-affinity binders may yield insufficient uptake. Marked heterogeneity within and between tumours further motivates redundancy (e.g., dual-ligand builds) and periodic reassessment as tumours evolve

MF-R-LNs can be engineered to release their payload in response to specific stimuli within the TME or external triggers. Common mechanisms include the following:pH sensitive lipids or polymers: exploit acidic tumour pH for membrane destabilisation;Redox sensitive linkers (e.g., disulfide bonds): cleaved by elevated intracellular glutathione [54];Enzyme-responsive elements: cleavable by matrix metalloproteinases (e.g., MMP-2/9), which are elevated in GBM during invasive growth, angiogenesis, and hypoxia-driven ECM remodelling; note that MMPs also rise in inflammatory CNS disorders (e.g., MS), so pair this trigger with tumour-targeting ligands or intracellular cues to preserve specificity [55,56];These mechanisms increase spatiotemporal control of drug delivery, reducing systemic toxicity and enhancing local therapeutic effect.

The modular nature of MF-R-LNs allows each functional element (core, coating, targeting ligand, release mechanism) to be tailored for a given therapeutic context. This platform can carry diverse payloads, including chemotherapeutics, gene agents (e.g., siRNA or CRISPR/Cas9 components), and immunomodulators. It also supports personalised designs for GBM heterogeneity by combining a BBB-transcytosis shuttle with at least one tumour-binding ligand and layered, stimulus-responsive release. Where profiling is limited or unavailable, a dual-ligand configuration provides a pragmatic default.

Therapeutic designs must also consider practical constraints, including the following:Manufacturability and scale-up. Reproducibility across batches is essential; detailed critical quality attributes (CQAs) and assays are outlined in Section 6.2.Hydrodynamic size and surface charge. A practical window of 80–150 nm with near-neutral to mildly negative ζ-potential can favour BBB interaction while limiting rapid reticuloendothelial system (RES) clearance [43].Colloidal and oxidative stability/leakage control. Use cholesterol-stabilised lipid blends (avoid storage/handling near the bilayer Tm) and validate leakage at 37 °C and under alternating magnetic fields (AMF); consider antioxidant lipids/additives where warranted.Core passivation and iron control. Prioritise passivated SPION cores (e.g., silica/dextran/phosphonate shells or equivalent) and minimise labile iron to mitigate Fenton-type chemistry (see Section 6.3).Regulatory and safety profiles. Component-level identity/purity/stability criteria and device documentation are required; AMF reporting conventions are summarised in Section 6.4.

Detailed good manufacturing practice/chemistry, manufacturing and controls (GMP/CMC), safety/immunogenicity, and regulatory/AMF reporting requirements are provided in,and(CQAs; PEG immunogenicity; SPION characterisation and MRI/MPI tracking; AMF parameters H, f, H × f, thermometry, calibration). Section 6.2 Section 6.3 Section 6.4

With these constraints defined, we next consider magnetic hyperthermia as a trigger, how SPION-mediated heating can be harnessed to enable controlled, on-target drug release (). Section 4

Thermosensitive lipids incorporated into the MF-R-LN bilayer can be designed to undergo phase transitions slightly above physiological temperatures (e.g., 42–45 °C) [18,57,58]. Upon AMF activation, SPION-mediated heating destabilises the membrane and triggers controlled drug release, enabling temporal precision so that release can be synchronised with tumour localisation (Figure 3). Typical alternating-magnetic-field parameters for SPION hyperthermia are 100–500 kHz at <15 kA·m⁻¹, with safety limits applied to avoid non-specific tissue heating.

Formulation choices should minimise baseline leakage at 37 °C while preserving a sharp release transition at the target temperature. In practice, this often requires blended lipid compositions with cholesterol for bilayer stabilisation, rather than relying on a single saturated lipid (e.g., DPPC alone). Optional polymeric over-layers (e.g., PNIPAM) can narrow the thermal window but add complexity and should be justified by leakage and release assays under physiologic and hyperthermic conditions. Overall, lipid composition, cholesterol fraction, ligand density, and particle size should be jointly tuned against stability vs. triggerability criteria established in vitro before in vivo use.

Magnetic hyperthermia may also contribute directly to tumour cell death via local heating. Even moderate hyperthermia (42 °C) can sensitise tumour cells to chemotherapy and radiotherapy by disrupting DNA repair pathways, increasing membrane permeability, and promoting apoptosis; inducing a local heat shock response [58,59]. At higher temperatures, thermal ablation can occur, although this requires more energy and may risk damaging surrounding healthy tissue.

GBM's dense extracellular matrix and irregular vascularization often create poorly perfused regions that are resistant to therapy. Hyperthermia may improve perfusion and oxygenation in these hypoxic zones, thereby enhancing drug penetration and overall treatment efficacy [60].

Effective magnetic hyperthermia requires careful optimisation of SPION characteristics and field conditions:Size and shape. Cores of approximately 10–20 nm remain superparamagnetic and minimise aggregation [61,62]; narrow polydispersity is preferred.Field parameters. Always report the field amplitude H (kA·m⁻¹), frequency f (kHz), their product H × f, and exposure duration, and target mild hyperthermia 42–45 °C at the lesion with verified thermometry.Surface modification. Biocompatible coatings reduce aggregation and opsonisation and improve colloidal stability and safety.Hybrid formulation. Embedding SPIONs within lipid matrices requires uniform dispersion and sustained stability [62,63]; lipid–magnetic hybrids enable guidance and stimulus-triggered release.

Magnetic-field safety. A commonly cited whole-body comfort heuristic is H × f ≤ 4.85 × 10⁸ A·m⁻¹·s⁻¹ (Atkinson–Brezovich). Focal, brain-targeted applications may operate above this with careful temperature monitoring; for example, clinical SPION hyperthermia has used H ≈ 18 kA·m⁻¹ and f ≈ 100 kHz (H × f ≈ 1.8 × 10⁹ A·m⁻¹·s⁻¹). As a practical upper bound, many groups remain below 5 × 10⁹ A·m⁻¹·s⁻¹ (Hergt–Dutz heuristic). In all cases, report the measured intratumoural temperature and the measurement method; numeric heuristics never replace thermal safety monitoring [61,64].

The ability to remotely control both nanoparticle localisation and drug release distinguishes MF-R-LNs from conventional delivery systems. By applying an external magnet or AMF, clinicians may enhance tumour accumulation via magnetic targeting and initiate payload release only after tumour localisation. This two-step strategy offers potential improvements in both selectivity and safety, reducing off-target toxicity and system side effects.

Surface ligands enhance cellular uptake by targeting overexpressed receptors on GBM cells and endothelial cells at the BBB. However, uptake alone does not guarantee therapeutic success, the cargo must be released intracellularly, ideally in response to tumour-specific cues. MF-R-LNs enable this through pH-, redox-, or enzyme-sensitive mechanisms, combined with externally applied magnetic hyperthermia to fine tune release kinetics.

The synergy between active targeting and stimuli-triggered release reduces premature leakage, improves tumour localisation, and increases intratumoural drug concentration, particularly in poorly perfused or hypoxic regions. The addition of magnetic guidance further enhances this selectivity by allowing non-invasive control over nanoparticle distribution.

While chemotherapy is the most obvious payload for MF-R-LNs, the platform is inherently flexible and can accommodate the following:Gene therapies (e.g., siRNA or plasmids targeting MGMT or EGFR);Immunomodulators (e.g., STING agonists or checkpoint inhibitors);Photothermal or radiotherapy sensitisers [2].

Multimodal therapy is especially relevant in GBM, where redundancy in survival pathways allows tumours to evade monotherapies. A single, modular system that co-delivers drugs and gene-silencers and releases them under tightly controlled conditions offers a rational response to tumour heterogeneity. With image guidance, otherwise prohibitive cytotoxic agents can be used more safely: magnetic guidance provides receptor-agnostic localisation, and the magnetic core is imageable (MRI/MPI), with MR thermometry during AMF to titrate exposure. See Table 1 for ligand options that support this strategy.

Because the MF-R-LN system is modular, its components can be personalised based on the molecular profile of an individual tumour. Ligand selection can be tailored to receptor expression, and release mechanisms can be adapted depending on microenvironmental conditions such as MMP levels or redox gradients. This adaptability could support personalised medicine approaches in GBM, where patient-to-patient variation is profound.

Future developments may also include "smart" feedback systems, in which drug release is dynamically adjusted in response to local temperatures, pH, or metabolic changes detected in real-time.

Where feasible, a minimal molecular profile—EGFR/EGFRvIII, IL-13Rα2, integrins αvβ3/αvβ5, and transcytosis targets (TfR/LRP1) by IHC or targeted RNA/NGS—can prioritise ligand selection. Map results to Table 1; if expression is low, heterogeneous, or unavailable, proceed without delay using a dual-ligand design (BBB shuttle + tumour-binding ligand) with redundancy.

In practice, early studies would prioritise recurrent GBM with supratentorial, measurable lesions away from eloquent cortex, managed on stable steroids/anticonvulsants. MF-R-LN infusion could be scheduled between radiotherapy fractions or in combination with temozolomide at recurrence, with one to three AMF sessions per cycle depending on thermal readouts. Safety monitoring would include neurological exam, adverse-event surveillance, and temperature limits to keep intratumoural peaks within 42–45 °C. MR thermometry (where available) or predefined surrogate triggers (time-at-field, SAR estimates) would gate session duration. These practical constraints inform dose escalation and scheduling.

In practice, first-in-human evaluation would prioritise recurrent/refractory GBM under a Phase 0/1 framework with image-guided localisation (conventional MRI/T2–FLAIR hypointensity or MPI) and MR-thermometry–titrated AMF, with standard field reporting (H, f, H × f).

Targeting ligands are critical for enhancing nanoparticle specificity and uptake, but their effectiveness is constrained by the heterogeneous nature of glioblastoma. Receptor expression varies widely not only between patients but also within tumour subregions, making it unlikely that a single ligand will ensure comprehensive targeting [65]. Over reliance on one receptor system may leave large fractions of the tumour unaddressed, particularly in invasive margins where expression profiles differ from the tumour core.

Multivalent or dual-ligand strategies may mitigate this issue, but at the cost of increased formulation complexity and potential off-target interactions [66]. Moreover, receptor saturation or downregulation following repeated exposure could reduce efficacy over time.

Each MF-R-LN component (lipid matrix, SPION core, PEGylation, ligand conjugation) introduces added synthesis and quality control requirements, and maintaining consistent size, surface charge, and ligand density is challenging at scale. Magnetic nanoparticles are prone to aggregation and require stabilising surface chemistries to remain colloidally stable in biological media; embedding them within lipid matrices without compromising bilayer integrity or inducing payload leakage necessitates careful optimisation. Large-scale production must ultimately meet GMP standards, which remains difficult for multifunctional, modular nanocarriers [61,67].

Translation will require a defined GMP/CMC package with batch-to-batch control of size/PDI/ζ-potential, ligand density (per particle), PEG density/cleavability, payload loading and release kinetics, and SPION content/relaxivity, alongside sterility/endotoxin and stability testing. CQAs and assays should be prespecified—e.g., DLS/NTA/SEC-MALS for size distributions, LC–MS for linker identity, ICP-MS/magnetometry for iron content and properties, and MRI relaxometry/MPI for tracking—while prioritising closed, scalable steps (in-line filtration, low-bioburden buffers) with complete batch records.

Although lipid-based systems and SPIONs are individually well studied, their combined use in multifunctional constructs raises additional toxicological questions. The long-term fate of iron oxide in brain tissue under repeated AMF exposure remains uncertain, with risks of oxidative stress, iron overload, and localised overheating [68]. Surface passivation, core size/valence control, and dosing strategies should be used to mitigate Fenton-type chemistry and unintended tissue effects.

PEGylation, once considered inert, can elicit anti-PEG antibodies, accelerating clearance or provoking hypersensitivity reactions [20]. Alternative stealth coatings, lower or cleavable PEG densities, and prospective immunosurveillance (e.g., anti-PEG titres) may reduce risk.

For uses involving alternating magnetic fields, authors should report H (kA·m⁻¹), f (kHz), H × f, exposure duration, and in situ thermometry to manage heating risk, and include device calibration/phantom data to document field uniformity and temperature accuracy.

Multifunctional nanomedicines are often regulated as combination products. Regulators will expect clear identity, purity, and stability criteria for each functional element (core, coating, linkers, ligands, payload) and for the assembled particle; validated release, immunogenicity, and safety assays; and predefined stopping rules for device-related heating. Even when components such as PEG, SPIONs, and phospholipids are individually familiar, the assembled construct carries additional burden due to potential synergy and emergent behaviour [17,61]. Device calibration/phantom documentation should accompany clinical use to demonstrate field uniformity and temperature accuracy.

Early clinical evaluation should prioritise recurrent/refractory GBM, where the risk–benefit is most favourable. A pragmatic Phase 0/1 approach can combine a small sentinel single-patient run-in with 3 + 3 or model-based dose escalation under Data and Safety Monitoring Board oversight. Co-primary endpoints are safety/tolerability and device/procedure feasibility; secondary readouts include intratumoural localisation (conventional MRI T2/FLAIR hypointensity or MPI), thermal-dose metrics via MR thermometry during AMF, PK/PD, and preliminary activity by Response Assessment in Neuro-Oncology (RANO).

A minimum preclinical package should precede first-in-human work: orthotopic GBM models for biodistribution, imageability, on-target heating, and efficacy; GLP toxicology (single and repeat dose), neurobehavioural testing, brain histopathology, iron fate/overload, and immunotoxicity (e.g., complement activation/anti-PEG); haemocompatibility/pyrogenicity assays; device–nanoparticle interaction testing (specific absorption rate, eddy-current effects, and H × f kept within practical heuristics); and, where feasible, large-animal studies for field dosimetry and skull-heating margins.

Therapeutic use of magnetic fields for guidance and hyperthermia requires specialised equipment and trained teams. While MRI and some local-heating systems are widespread, adapting field generators for treatment remains niche and logistically demanding. Ensuring that therapeutic heating remains within safe, effective temperature ranges across heterogeneous tissues is non-trivial and may necessitate individualised calibration and on-line thermometry. Moreover, dedicated hyperthermia infrastructure is not yet standard in most oncology centres, which may limit access and scale-up, particularly in resource-limited settings [69].